Chimerix (NASDAQ:CMRX) Now Covered by StockNews.com

Analysts at StockNews.com assumed coverage on shares of Chimerix (NASDAQ:CMRX) in a research note issued to investors on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

A number of other research firms have also recently issued reports on CMRX. HC Wainwright reiterated a “neutral” rating and issued a $8.55 target price (down previously from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. Wedbush reiterated a “neutral” rating and issued a $8.55 target price (up previously from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $8.50 target price (down previously from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Stock Performance

CMRX opened at $8.50 on Friday. The company has a market capitalization of $764.46 million, a P/E ratio of -9.04 and a beta of 0.32. The stock has a fifty day moving average of $5.34 and a 200-day moving average of $2.84. Chimerix has a fifty-two week low of $0.75 and a fifty-two week high of $8.52.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. The company had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.31 million. On average, equities research analysts predict that Chimerix will post -0.99 earnings per share for the current fiscal year.

Insider Transactions at Chimerix

In other news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the sale, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last three months, insiders have sold 20,760 shares of company stock worth $91,175. Insiders own 13.10% of the company’s stock.

Institutional Trading of Chimerix

Several hedge funds and other institutional investors have recently made changes to their positions in CMRX. Deerfield Management Company L.P. Series C bought a new stake in shares of Chimerix during the fourth quarter worth about $13,124,000. Rosalind Advisors Inc. bought a new stake in Chimerix in the fourth quarter valued at approximately $10,614,000. Boxer Capital Management LLC bought a new stake in Chimerix in the fourth quarter valued at approximately $7,169,000. Marshall Wace LLP boosted its holdings in Chimerix by 1,318.5% in the fourth quarter. Marshall Wace LLP now owns 2,213,940 shares of the biopharmaceutical company’s stock valued at $7,705,000 after acquiring an additional 2,057,864 shares during the last quarter. Finally, Peapod Lane Capital LLC bought a new stake in Chimerix in the fourth quarter valued at approximately $2,626,000. 45.42% of the stock is currently owned by institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.